KOEDA Secures Mitsubishi UFJ Capital for GI Anchor Technology

In a significant development for minimally invasive gastrointestinal procedures, KOEDA has secured a new round of investment from Mitsubishi UFJ Capital. This capital infusion is earmarked to accelerate the development and commercialization of the company's innovative organ fixation anchors, designed to enhance the safety and efficacy of endoscopic treatments for complex gastrointestinal conditions.

The core of KOEDA's technology is a novel, ultra-thin anchor, measuring just 1mm in diameter. This device is engineered for insertion via endoscopic ultrasound (EUS) puncture needles, facilitating precise organ stabilization. Its primary application targets EUS-guided gallbladder drainage (EUS-GBD), a critical intervention for conditions like acute cholecystitis. By securely affixing the gallbladder to adjacent organs such as the stomach or duodenum, the anchor aims to mitigate significant risks, including bile leakage and device displacement, which can complicate recovery.

Market analysis indicates a growing demand for advanced endoscopic solutions. The global minimally invasive surgery market, encompassing gastrointestinal interventions, is projected to reach substantial figures in the coming years, driven by patient preference for less invasive options and technological advancements. KOEDA's technology directly addresses a key challenge in EUS-GBD, a procedure gaining traction as an alternative to traditional surgery for high-risk patients.

Evidence supporting the device's potential is emerging from early clinical evaluations. An exploratory trial, designated KOEDA01, conducted at Sendai Kousei Hospital, concluded in May 2025. Preliminary findings suggest that patients undergoing EUS-GBD with the KOEDA anchor subsequently proceeded to laparoscopic cholecystectomy without requiring conversion to open surgery. This outcome underscores the device's promise in terms of both safety and procedural success, paving the way for broader clinical adoption.

The newly acquired funds will be strategically deployed across several key initiatives. A substantial portion will support a domestic confirmatory clinical trial, crucial for gathering robust data for regulatory submissions. Concurrently, efforts will focus on strengthening the company's Quality Management System (QMS) to meet stringent manufacturing standards and preparing for a pivotal market entry into the United States. KOEDA anticipates obtaining domestic manufacturing and marketing approval between 2027 and 2028, marking a significant milestone.

This funding round follows previous support for KOEDA, including an investment from Tohoku University Venture Partners in June 2024. The company's leadership, notably Representative Director Toru Okuzono, brings a unique blend of clinical expertise and entrepreneurial vision. Okuzono, also Chief of Gastroenterology at Sendai Kousei Hospital and the principal investigator for the KOEDA01 trial, provides invaluable insights into the practical needs of endoscopic interventions.

The strategic involvement of Mitsubishi UFJ Capital highlights the growing investor confidence in medtech innovations addressing unmet clinical needs. As the healthcare landscape continues to prioritize patient outcomes and cost-effectiveness, technologies like KOEDA's organ fixation anchors are poised to play an increasingly vital role in shaping the future of gastrointestinal disease management.